Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Predictive Clinical and Biological Parameters in Breast Cancer (BC-BIO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Institut Paoli-Calmettes
Sponsor:
Information provided by (Responsible Party):
Institut Paoli-Calmettes
ClinicalTrials.gov Identifier:
NCT01521676
First received: December 22, 2011
Last updated: December 31, 2013
Last verified: December 2013

December 22, 2011
December 31, 2013
December 2010
December 2016   (final data collection date for primary outcome measure)
molecular alteration in breast cancer [ Time Frame: average of 4 weeks after diagnosis ] [ Designated as safety issue: No ]
gene expression level
Same as current
Complete list of historical versions of study NCT01521676 on ClinicalTrials.gov Archive Site
relation between molecular alteration and clinical and histological characteristics [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
hazard ratio between molecular alteration and clinical and histological characteristics
Same as current
Not Provided
Not Provided
 
Predictive Clinical and Biological Parameters in Breast Cancer
Research of Predictive Clinical and Biological Parameters in Breast Cancer

Research of predictive clinical and biological factors in breast cancer :

genomic, proteomic, mutation

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Breast Cancer
Genetic: molecular alteration
research of molecular alteration
Other Name: molecular alteration
Experimental: breast cancer
blood and tumor sample
Intervention: Genetic: molecular alteration
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
December 2026
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • breast cancer
  • age > 18
  • signed informed consent

Exclusion Criteria:

  • emergency
Both
18 Years and older
No
Contact: Dominique GENRE, MD 33491223778 drci.up@ipc.unicancer.fr
Contact: Agnès BOYER CHAMMARD, MD 33491223778 drci.up@ipc.unicancer.fr
France
 
NCT01521676
BC-BIO/IPC 2009-005
No
Institut Paoli-Calmettes
Institut Paoli-Calmettes
Not Provided
Principal Investigator: Carole TARPIN, MD Institut Paoli-Calmettes
Institut Paoli-Calmettes
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP